

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete If Known	
			Application Number	09/581,651
			Filing Date	June 15, 2000
			First Named Inventor	Schor et al.
			Art Unit	1642
			Examiner Name	Steven L. Rawlings
1	of	3	Attorney Docket Number	350013-72

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ³ (if known)	Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
SR	1	US-4,980,279	12/25/90	PETERS et al.
	2	US-5,049,658	09/17/91	KIMIZUKA et al.
	3	US-5,124,155	06/23/92	REICH, Cary
	4	US-5,300,630	04/05/94	MATSUURA et al.
	5	US-5,571,679	11/05/96	SEKIGUCHI et al.
↓	6	US-5,629,291	05/13/97	RUOSLAHTI et al.

RECEIVED

APR 01 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
SR	7	EPO - 0 207 751	06/27/86	BARELLA, Francisco
	8	EPO - 0 344 134	05/25/89	ZARDI, Luciano
	9	PCT - WO 90/00567	01/25/90	SCHOR et al.
	10	PCT- WO 94/16085	07/21/94	IRANI, Meher
↓	11	PCT - WO 99/02674	01/21/99	SCHOR, Seth

Examiner Signature	<i>SR</i>	Date Considered	11/15/04
--------------------	-----------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449B/PTO			Complete if Known	
Information Disclosure Statement by Applicant <small>(use as many sheets as necessary)</small>			Application Number	09/581,6511
			Filing Date	June 15, 2000
			First Named Inventor	Schor et al.
			Group Art Unit	1642
			Examiner Name	Stephen L. Rawlings
Sheet 1 of 3	of 3		Attorney Docket Number	350013-72

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
RECEIVED		
APR 01 2002 SR	12	KORNBLIHTT, et al., Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene, EMBO Sequence Database Accession No. X0271; 4:1755-1759 (1985)
TECH CENTER 1600/2900	13	KORNBLIHTT et al., Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene, EMBO, (USA) vol. 4 pp. 1755-1759 (1985)
SR	14	KORNBLIHTT et al., SWISSPROT Sequence Database Accession No. P02751, (1986)
	15	PIRI Sequence database (1985) Accession Ref. FNH1U
	16	DEAN et al., Cloning and analysis of the promoter region of the human fibronectin gene; Proc. Natl. Acad. Sci. USA, Vol. 84, pp. 1876-1880, April 1987
	17	HYNES et al., EMBL Data library PIR2 Accession No. S14428, 1989
	18	DESIMONE et al., Identification and characterization of alternatively spliced fibronectin mRNAs expressed in early Xenopus embryos, SWISSPROT Database Accession Ref. FINC_XENLA, Dev. Biol. vol. 149 pp. 357-369 (1992)
	19	SCHOR, Fibroblast subpopulations as accelerators of tumor progression: The role of migration stimulating factor, Epithelial-Mesenchymal Interactions in Cancer, 1995 pp. 273-296, Switzerland
	20	SCHOR et al., Migration stimulating factor (MSF): Its structure mode of action and possible function in health and disease; The Society of Experimental Biology 1993, pp. 235-251, UK
	21	GREY et al., Purification of the migration stimulating factor produced by fetal and breast cancer patients fibroblasts, Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 2438-2422, April 1989
	22	SCHOR et al., Fetal-like fibroblasts: their production of migration stimulating factor and role in tumor progression, Mammary Tumorigenesis and Malignant Progression, pp. 277-298, 1994
	23	IRWIN et al., Inter-and Intra-site heterogeneity in the expression of fetal-like phenotypic characteristic by gingival fibroblasts: potential significance for wound healing, Journal of Cell Science, Vol 107, p 1333-1346 (1994) UK
	24	SCHOR et al., Phenotypic heterogeneity in breast fibroblasts: Functional anomaly in fibroblasts from histologically normal tissue adjacent to carcinoma, Int. J. Cancer, Vol. 59, pp. 25-32 (1994)
	25	PICARDO et al., Migration stimulating activity in serum of breast cancer patients, The Lancet, Vol. 337, pp. 130-134, January 19, 1991

12 11/15/04

Substitute for form 1449B/PTO			Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			Application Number	09/581,6511
			Filing Date	June 15, 2000
			First Named Inventor	Schor et al.
			Group Art Unit	1642
			Examiner Name	Stephen L. Rawlings
			Attorney Docket Number	350013-72
Sheet 1 of 3		of 3		

RECEIVED

APR 01 2002 SR
TECH CENTER 1600/2900

SR	26	ELLIS et al., Autognostic effects of TGF- β 1 and MSF on fibroblast migration and hyaluronic acid synthesis, Possible implications for dermal wound healing, Journal of Cell Science, Vol. 102, pp. 447-45 (1992) UK
SR	27	PICARDO et al., Detection of migration stimulating activity in wound fluid, Experimental and Molecular Pathology Vol. 57, pp 8-21 (1992)
SR	28	SCHOR et al., Heterogeneity amongst fibroblasts in the production of migration stimulating factor (MSF): Implications for cancer pathogenesis, Cell Motility Factors, pp. 127-146, 1992
SR	29	SCHOR et al., Fibroblasts from cancer patients display a mixture of both foetal and adult-like phenotypic characteristics; Journal of Cell Science, Vol. 90, pp. 401-407 (1988) UK
SR	30	SCHOR et al., Foetal and cancer patient fibroblasts produce an autocrine migration stimulating factor not made by normal adult cells, Journal of Cell Science, Vol. 90, pp. 391-399 (1988) UK
	31	SCHOR et al., Characterization of migration-stimulating factor (MSF): Evidence of its role in cancer pathogenesis, Cancer Investigation Vol. 8(6), pp. 665-667, (1990)
▼	32	SCHOR et al., Mechanism of action of the migration stimulating factor produced by fetal and cancer patient fibroblasts: Effect on hyaluronic acid synthesis, In Vitro Cellular Development and Biology, Vol 25, Number 8, pp. 737-746, August 1989

Examiner Signature	<i>[Signature]</i>	Date Considered	11/15/04
--------------------	--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.